Comparison of apolipoprotein B and plasma lipids as targets for lipid lowering treatment

Clinical Biochemistry

Volumn 38, Issue 6, 2005, Pages 509-513

  Vaverkova, Helena ^a   Frohlich, Jiri ^b   Jackuliakova, Dagmar ^a   Novotny, Dalibor ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Apo B; Apo B targets; Diabetes; Hypertriglyceridemia; LDL C targets

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; COLESTIPOL; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG TARGETING; FEMALE; GLUCOSE HOMEOSTASIS; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROTEIN TARGETING;

ADULT; AGED; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FASTING; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTRIGLYCERIDEMIA; MIDDLE AGED; TRIGLYCERIDES;

EID: 18844385693     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2005.02.012     Document Type: Article

References (43)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
2. G. De Backer, E. Ambrosioni, and K. Borch-Johnsen European guidelines on cardiovascular disease prevention in clinical practice Eur. Heart J. 24 2003 1601 1610
3. M.A. Austin, J.L. Breslow, and C.H. Hennekens Low-density lipoprotein subclass patterns and risk of myocardial infarction JAMA 260 1988 1917 1921
4. H. Campos, J.J. GenestJr, and E. Blijlevens Low density lipoprotein particle size and coronary artery disease Arterioscler. Thromb. 12 1992 187 195
5. J. Coresh, P.O. Kwiterowich, H.H. Smith, and P.S. Bachorik Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women J. Lipid Res. 34 1993 1687 1697
6. R.H. Superko Lipoprotein subclasses and atherosclerosis Front. Biosci. 6 2001 D355 D365
7. R.M. Krauss Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk Curr. Opin. Lipidol. 5 1994 339 349
8. C. Packard, M. Caslake, and J. Shepherd The role of small, dense low density lipoprotein (LDL): a new look Int. J. Cardiol. 74 Suppl. 1 2000 S17 S22
9. B. Lamarche, A. Tchernof, and S. Moorjani Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study Circulation 95 1997 69 75
10. C.D. Gardner, S.P. Fortmann, and R.M. Krauss Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women J. Am. Med. Assoc. 276 1996 875 881
11. M.J. Stampfer, R.M. Krauss, J. Ma, P.J. Blanche, L.G. Holl, and F.M. Sacks A prospective study of triglyceride level, low density lipoprotein particle diameter, and risk of myocardial infarction J. Am. Med. Assoc. 276 1996 882 888
12. L. Mykkanen, J. Kuusisto, and S.M. Haffner LDL size and risk of coronary heart disease in elderly men and women Arterioscler. Thromb. Vasc. Biol. 19 1999 2742 2748
13. M.A. Austin, B.L. Rodriguez, and B. McKnight Low density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men Am. J. Cardiol. 86 2000 412 416
14. B. Lamarche, A. St-Piere, and I. Ruel A prospective, population-based study of low-density lipoprotein particle size as a risk factor for ischemic heart disease in men Can J. Cardiol. 17 2001 859 865
15. P.J. Talmud, E. Hawe, G.J. Miller, and S.E. Humphries Non-fasting apo B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men Arterioscler. Thromb. Vasc. Biol. 22 2002 1918 1923
16. G. Waldius, I. Jungner, and I. Holme High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2001 2026 2033
17. B. Lamarche, S. Moorjani, and P.J. Lupien Apolipoprotein A-1 and B levels and the risk of ischemic heart disease during a five year follow-up of men in Québec Cardiovascular Study Circulation 94 1996 273 278
18. A.J. Moss, R.E. Goldstein, and V.J. Marder Thrombogenic factors and recurrent coronary events Circulation 99 1999 2517 2522
19. A.M. Gotto, E. Whitney, E.A. Stein, D.R. Shapiro, M. Clearfield, and S. Weis Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 2000 477 484
20. J.E. Roeters van Lennep, T. Westerveld, and W.O. Roeters van Lennep Apolipoprotein concentrations during treatment and recurrent coronary artery disease events Arterioscler. Thromb. Vasc. Biol. 20 2000 2408 2413
21. R.J. Simes, I.C. Marschner, and D. Hunt Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in the Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105 2002 1162 1169
22. J. Genest, J. Frohlich, G. Fodor, and R. McPherson Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update CMAJ 169 2003 921 924
23. S.M. Grundy Low density lipoprotein, non-high density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy Circulation 106 2002 2526 2529
24. D. Wood, G. De Backer, and O. Faergeman Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention Eur. Heart J. 19 1998 1434 1503
25. W.T. Friedewald, R.I. Levy, and D.S. Frederickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge Clin. Chem. 18 1972 499 502
26. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
27. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N. Engl. J. Med. 335 1996 1001 1009
28. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N. Engl. J. Med. 339 1998 1349 1357
29. West of Scotland Coronary Prevention Study Group Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation 97 1998 1440 1445
30. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
31. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
32. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N. Engl. J. Med. 350 15 2004 1495 1504
33. S.M. Grundy, J.I. Cleeman, and C.N.B. Merz Implication of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 110 2004 227 239
34. C.M. Ballantyne, T.C. Andrews, J.A. Hsia for the ACCESS Study Group Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels Am. J. Cardiol. 88 2001 265 269
35. S.E. Nissen, E.M. Tuzcu, and B.G. Brown Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis JAMA 291 2004 1071 1080
36. A.D. Sniderman, C.D. Furberg, and A. Keech Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment Lancet 361 2003 777 780
37. G. Walldius, and I. Jungner Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy J. Intern. Med. 255 2004 188 205
38. A.D. Sniderman, T. Scantlebury, and K. Cianflone Hypertriglyceridemic heperapoB: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus Ann. Intern. Med. 135 2001 447 459
39. S. Miremadi, A. Sniderman, and J. Frohlich Can measurement of serum apolipoprotein B replace the lipid profile monitoring of patients with lipoprotein disorders? Clin. Chem. 48 2002 484 488
40. S.M. Marcovina, J.J. Albers, H. Kennedy, J.V. Mei, L.O. Henderson, and W.H. Hannon International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material Clin. Chem. 40 1994 586 592
41. K. Skalén, M. Gustafsson, E.K. Rydberg, L.M. Hultén, O. Wiklund, and T.L. Innerarity Subendothelial retention of atherogenic lipoproteins in early atherosclerosis Nature 417 2002 750 754
42. V. Anber, B.A. Griffin, M. McConnell, C.J. Packard, and J. Shepherd Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans Atherosclerosis 124 1996 261 271
43. M.M. Veniant, M.A. Sullivan, S.K. Kim, A.C. Ambroziak, M.D. Wilson, and M.K. Hellerstein Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100 J. Clin. Invest. 106 2000 1501 1510